Skip to main content
Equibles
SMMT logo

SMMT · Summit Therapeutics Inc.

Track SMMT — free Ask ALVIS about SMMT
$12.79 +0.24 (+1.91%)
Market Cap
$10.01B
Shares
797.75M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.55 Open$13.01 Day$12.25–13.05 52W$12.25–30.98 Avg vol 30d4.7M Short int37.3M · 4.7% float · 11.0d Short vol70% Last earningsJul 23, 2026 DataJan 2020–Jul 2026 Filing10-Q · Jul 23

Up next

Next earnings call
Nov 12, 2026 Est · unconfirmed · in 15 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 23, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Strong Sell
      SellHoldBuy
      Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 18.2 · elevated Equity put/call 0.71
      Technical
      price trend
      Strong Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −27%
      below
      Price vs 50-day avg −16%
      below
      RSI (14) 34
      neutral
      MACD trend Negative
      52-week position 2%
      near low
      Momentum
      relative strength
      Very Weak
      1-month return −13%
      trailing
      6-month return −14%
      trailing
      YTD return −28%
      this year
      Relative strength −21%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $15 › 200d $17 — 200d above 50d
      Institutional flow Distributing
      42 of 226 funds reported for Jun 30 · net -142.3K sh shares · +4 new
      Insider flow Accumulating
      Net +$103.6M over 90 days · 0% sells
      Short interest Falling
      4.68% of float · ▼ -6.3% MoM · 11.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      226 holders — mid 3-yr range
      Squeeze score 58
      elevated · 0–100
      Fundamentals
      Weak
      EPS growth −365%
      Y/Y
      Free cash flow $-323.6M
      Balance sheet $225.3M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 73%
      annualized · 1-yr
      Max drawdown −57%
      past year
      ATR 7.3%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Strong Sell
      4 · 2 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −27% Bearish
      Price vs 50-day avg
      −16% Bearish
      RSI (14)
      34 Neutral
      MACD trend
      Negative Bearish
      52-week position
      2% Bearish
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $15 › 200d $17 — 200d above 50d
      Institutional flow Distributing
      42 of 226 funds reported for Jun 30 · net -142.3K sh shares · +4 new
      Insider flow Accumulating
      Net +$103.6M over 90 days · 0% sells
      Short interest Falling
      4.68% of float · ▼ -6.3% MoM · 11.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      226 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $12 Now $13 · 2% 52-wk high $31
      vs 200-day avg -27% vs 50-day avg -16%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Aggregate cash and cash equivalents and short-term investments $713.4M December 31, 2025 —
      Non-GAAP G&A expenses non-GAAP $42.8M full year 2025 —
      Non-GAAP net loss non-GAAP $347.2M full year 2025 —
      Non-GAAP R&D expenses non-GAAP $319.2M full year 2025 —
      patients treated in a commercial setting with ivonescimab in China 60,000 since in-licensing in January 2023 —
      patients treated with ivonescimab in clinical studies globally 4,000 since in-licensing in January 2023 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      SMMT
      Summit Therapeutics Inc.
      this stock
      		$10.01B -28.2% — — 4.7%
      ONC
      BeOne Medicines Ltd.
      		 $474.96B +8.8% +22179.2% 966.6 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $124.46B +8.2% +46.2% 29.1 2.0%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $72.88B -9.8% +20.8% 17.0 3.3%
      ARGX
      Argenx SE
      		 $54.57B +3.7% — — 2.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      221
      % held
      14.7%
      Reported
      42 of 226
      Top holder
      BAKER BROS. ADVISORS LP
      Held Float
      View
      Held by Funds
      Fund positions
      190
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      37.3M
      Days to cover
      11.0d
      Change
      -2.5M sh
      View
      Short Volume
      Short vol %
      70%
      As of
      Jul 28, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      24.0K
      Value
      $344.2K
      As of
      Jun 30, 2026
      View
      Off-Exchange
      Off-exchange %
      40.5%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Cluster buy
      Net (90d)
      +$103.6M
      Buyers / Sellers
      3 / 0
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $0
      Net income (FY)
      $-1.1B
      EPS diluted
      $-1.44
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 23, 2026
      This year
      16
      View
      Exempt Offerings
      Offering
      $235.0M
      Filed
      Sep 26, 2024
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 23, 2026
      View
      Investor Relations
      Latest news
      Summit Therapeutics Reports Finan…
      Published
      Jul 23, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      SMMT -14.2% -12.9% -14.0% -13.9% -28.2%
      SPY -1.0% 0.0% +7.4% -0.8% +8.6%
      vs SPY -13.2% -12.8% -21.4% -13.1% -36.9%
      Key facts CIK 1599298 CUSIP 86627T108 13F (30d) 33 filings 33 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)